Clinical trials: Cytomegalovirus Prophylaxis, open to volunteers
Kidney Transplant, Liver Transplant
Letermovir for R+ Study
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been…
- Trial name
- MISP CMV (NCT07706166)
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- University of Wisconsin, Madison
CMV
Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT).
- Trial name
- INMUNOCELL (NCT04056533)
- Testing
- CMV CTLs
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients
Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus.
The overall objective of this project is to optimise preventive treatment of CMV infection/disease in renal transplant recipients at increased risk of CMV post-transplantation.
- Trial name
- NCT07203664
- Testing
- steroids, tacrolimus and mTOR inhibitors, steroids, tacrolimus and mycophenolic acid.
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario La Paz
Cytomegalovirus, Organ Transplant
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver…
- Conditions
- Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications
- Trial name
- SHIELD (NCT06958796)
- Testing
- Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Camille N. Kotton, MD
Cell Therapy
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.
- Trial name
- NCT06575374
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Transplant; Complications
CMV Immunity Monitoring in Lung Transplant Recipients
The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant.
- Trial name
- NCT05708755
- Testing
- Cytomegalovirus T Cell Immunity Panel (CMV-TCIP), Donor-Derived Cell-Free DNA (dd-cfDNA) Assay, Valganciclovir
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NYU Langone Health
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Cytomegalovirus Infections, CMV
Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT
After allogeneic hematopoietic stem cell transplantation (allo-HSCT), recipients are immunocompromised and at increased risk of complications, including cytomegalovirus (CMV) infection.
- Trial name
- NCT06812598
- Testing
- Letermovir (0-24w）, Letermovir (0-14w）
- Where
- China
- Volunteers
- 330 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hematologic Malignancies
Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients
Patients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT).
- Trial name
- NCT07709013
- Testing
- Leflunomide 20 mg
- Where
- 3 sites in India
- Volunteers
- 22 people
- Sponsor
- Tata Memorial Centre
CMV Infection, CMV
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropositive.
- Conditions
- CMV Infection, CMV, CMV Viremia, CMV Disease
- Trial name
- NCT07571135
- Testing
- Letermovir, Valganciclovir CMV Prophylaxis
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Elisabeth Kincaide
Cytomegalovirus Cell Mediated Immunity, Stem Cell Transplantation, Hematopoietic
Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND)
Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (SCT). Fixed-duration letermovir (LTV) prophylaxis during the first 100 days post-SCT is effective and safe…
- Trial name
- INMUNOEND (NCT06814301)
- Testing
- Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
- Where
- Spain
- Volunteers
- 123 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Kidney Transplant
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
the existing anti-CMV drugs mainly include valganciclovir, ganciclovir and foscarnet sodium, all of which act on DNA polymerase (pUL54), making them prone to cross resistance.
- Trial name
- CAPS01 (NCT07266467)
- Testing
- Letermovir, Valganciclovir
- Where
- China
- Volunteers
- 290 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant compared to estimated…
- Trial name
- NCT05711667
- Testing
- Biospecimen Collection, Letermovir
- Where
- 33 sites in United States
- Volunteers
- 105 people
- Sponsor
- Children's Oncology Group
Cytomegalovirus Infections
Breakthrough CMV Lung Transplant -Multicentre
Cytomegalovirus (CMV) infection is the most common opportunistic infection in lung transplantation leading to direct and indirect effects that can result in life threatening complications.
- Trial name
- NCT04439916
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
Cytomegalovirus (CMV), Kidney Transplant; Complications
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR).
- Conditions
- Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases
- Trial name
- KPoP (NCT06798909)
- Testing
- Valganciclovir (Pre-emptive CMV Therapy), Valganciclovir CMV Prophylaxis
- Where
- 8 sites in United States
- Volunteers
- 360 people
- Sponsor
- University of California, San Francisco
Cytomegalovirus Infections, Cytomegalovirus Disease
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
The purpose of this study is to evaluate the efficacy and safety of a personalized strategy for discontinuing Letermovir (a drug used to prevent Cytomegalovirus [CMV] infection) based on the recovery of the patient's own immune…
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
- Trial name
- NCT07569653
- Testing
- CMV-Specific T-cell Guided Letermovir Discontinuation, Standard Letermovir Prophylaxis
- Where
- 12 sites in China
- Volunteers
- 120 people
- Sponsor
- WeiShi
Cytomegalovirus Prophylaxis
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds).
- Trial name
- NCT07199465
- Testing
- Letermovir
- Where
- 22 sites in United States
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Immunoglobulin Prophylaxis, Cytomegalovirus Infections
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region…
- Conditions
- Immunoglobulin Prophylaxis, Cytomegalovirus Infections, Allogeneic Hematopoietic Stem Cell Transplantation, Transplant-Related Disorder
- Trial name
- NCT07013370
- Testing
- Anti-CMV immunoglobulins [Megalotect (R)]
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Antonello Di Paolo, M.D., Ph.D.
CMV Infection
Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration
With the increasing use of letermovir and considering that haploidentical hematopoietic stem cell transplantation (haplo-HSCT) predominates in China alongside a high CMV seroprevalence in the population, multiple domestic centers…
- Trial name
- NCT07443501
- Volunteers
- 1,114 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lung Diseases
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus…
- Trial name
- NCT06494033
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami